Assessing the subjective intensity of oral psilocybin in patients with treatment-resistant depression: a pilot study (PSILODEP-PILOT)

Open-label, interventional Phase II pilot in treatment-resistant major depression testing two single oral doses of psilocybin (10 mg and 25 mg) given one week apart in the same participants.

Primary outcome: QIDS measured at baseline, one day and one week post-dose; secondary outcomes include BDI, HAM-D and MADRS. Safety and tolerability were reported and multiple peer-reviewed results publications are linked to the registry record.